| Serial Number | 79407494 |
| Word Mark | MAXORPTION |
| Filing Date | Monday, July 29, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Tuesday, September 16, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical and veterinary preparations containing omega 3 for treatment of cardiovascular diseases, cognitive decline, and inflammatory disorders; dietetic foods for medical use containing oils rich in EPA and DHA for treating dyslipidemia, metabolic syndrome, and neurodevelopmental disorders; nutritional supplements for human consumption for medical use containing oils rich in EPA and DHA that are of marine or microalgae origin for treating cardiovascular and metabolic disorders namely hypertriglyceridemia, metabolic syndrome, and type 2 diabetes, neurological and cognitive decline namely Alzheimer's disease and mild cognitive impairment, mood and psychiatric disorders namely depression and anxiety, inflammatory and autoimmune conditions namely rheumatoid arthritis and inflammatory bowel disease, and ophthalmic disorders namely dry eye syndrome and age-related macular degeneration; ophthalmic preparations containing omega-3; food supplements for medical use containing oils rich in EPA and DHA that are of marine or microalgae origin for treating cardiovascular diseases namely hypertriglyceridemia and atherosclerosis, neurodegenerative disorders namely Alzheimer's disease and cognitive decline, psychiatric conditions namely depression and anxiety, inflammatory and autoimmune diseases namely rheumatoid arthritis, and for supporting maternal and infant health namely healthy pregnancy, reduction of risk of preterm birth, optimal fetal brain and retinal development, and post-partum mental health; food supplements for specialized nutrition, infant nutrition; Nutraceuticals containing oils rich in EPA and DHA, targeting the microbiota for treating inflammatory bowel disease, irritable bowel syndrome and metabolic inflammation and intestinal dysbiosis; Nutritional dietetic food additives for medical, paramedical or pharmaceutical use in the nature of natural food extracts derived from fish; food supplements containing omega-3; food supplements derived from microalgae or marine oils |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 24, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | POLARIS |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | FR |
| Event Date | Event Description |
| Thursday, October 24, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, October 25, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Sunday, February 9, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, March 17, 2025 | REFUSAL PROCESSED BY MPU |
| Monday, March 17, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, October 25, 2024 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, February 4, 2025 | ASSIGNED TO EXAMINER |
| Friday, February 7, 2025 | NON-FINAL ACTION WRITTEN |
| Saturday, April 5, 2025 | REFUSAL PROCESSED BY IB |
| Tuesday, September 16, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, September 16, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, September 16, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |